CeriBell, Inc. (NASDAQ:CBLL) Short Interest Down 13.8% in March

CeriBell, Inc. (NASDAQ:CBLL) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 1,659,720 shares, a decline of 13.8% from the February 26th total of 1,925,021 shares. Based on an average daily trading volume, of 318,243 shares, the days-to-cover ratio is currently 5.2 days. Approximately 5.5% of the company’s stock are sold short.

CeriBell Stock Performance

NASDAQ CBLL traded up $0.16 during trading hours on Tuesday, hitting $17.92. The company had a trading volume of 43,847 shares, compared to its average volume of 328,668. The business has a 50 day moving average of $19.61 and a 200-day moving average of $17.30. The company has a market cap of $674.32 million, a PE ratio of -12.18 and a beta of 1.13. CeriBell has a 1-year low of $10.01 and a 1-year high of $24.33. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The business had revenue of $24.78 million for the quarter, compared to analysts’ expectations of $23.95 million. As a group, equities research analysts expect that CeriBell will post -2.46 EPS for the current year.

Insider Activity

In other CeriBell news, CTO Raymond Woo sold 8,087 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $18.25, for a total value of $147,587.75. Following the sale, the chief technology officer directly owned 166,912 shares in the company, valued at $3,046,144. This trade represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Josef Parvizi sold 16,714 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total value of $338,792.78. Following the completion of the transaction, the director owned 722,652 shares in the company, valued at approximately $14,648,156.04. The trade was a 2.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 203,627 shares of company stock valued at $4,156,660. 20.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell in the 3rd quarter valued at $33,000. CWM LLC raised its position in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group raised their price objective on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.